Rite Aid Corporation (RAD)
(Delayed Data from NYSE)
$8.77 USD
-0.03 (-0.34%)
Updated May 3, 2019 04:02 PM ET
After-Market: $8.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.77 USD
-0.03 (-0.34%)
Updated May 3, 2019 04:02 PM ET
After-Market: $8.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Has Rite Aid (RAD) Outpaced Other Retail-Wholesale Stocks This Year?
by Zacks Equity Research
Is (RAD) Outperforming Other Retail-Wholesale Stocks This Year?
Why Rite Aid (RAD) Could Be Positioned for a Surge
by Zacks Equity Research
Rite Aid (RAD) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
4 Reasons Why You Should Add Rite Aid to Your Portfolio
by Zacks Equity Research
Rite Aid (RAD) is gaining from efforts to enhance customers' shopping in these trying times. Also, it is progressing well with the EnvisionRxOptions strategy.
Is the Options Market Predicting a Spike in Rite Aid (RAD) Stock?
by Zacks Equity Research
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
Will Rite Aid Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Rite Aid Corporation
Top Ranked Momentum Stocks to Buy for June 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 30th:
New Strong Buy Stocks For June 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Rite Aid's (RAD) Q1 Loss Narrower Than Expected, Sales Up Y/Y
by Zacks Equity Research
Rite Aid's (RAD) Q1 results gain from increased prescription deliveries, as its stores remained open amid COVID-19. However, it withdraws the fiscal 2021 view due to uncertain COVID-19 impacts.
Rite Aid (RAD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of 92.59% and 7.66%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Lay Z Boy, Winnebago, KB Home and Rite Aid
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Lay Z Boy, Winnebago, KB Home and Rite Aid
How Is the U.S. Consumer? Global Week Ahead
by John Blank
For me, the U.S. companies to watch for 2020 earnings and revenue growth catalysts are solid growth-ranked major companies, in a variety of consumers spaces.
Factors Setting the Tone for Rite Aid's (RAD) Q1 Earnings
by Zacks Equity Research
Rite Aid's (RAD) Q1 performance is likely to gain from its delivery services amid the ongoing COVID-19 crisis. However, weak EBITDA remains a concern.
Rite Aid (RAD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Rite Aid (RAD) closed at $12.61, marking a +0.88% move from the previous day.
Earnings Preview: Rite Aid (RAD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Rite Aid (RAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rite Aid (RAD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed the most recent trading day at $13.17, moving +1.23% from the previous trading session.
Rite Aid Adds More Testing Sites in Fight Against Coronavirus
by Zacks Equity Research
Rite Aid (RAD) is aggressively expanding COVID-19 testing locations by adding 21 more sites in order to curb the effects of coronavirus.
Pharmacies & Drug Stores Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Amid the coronavirus-led worldwide sales disruption, the retail pharmacy and drug store industry is witnessing a bloodbath.
Rite Aid (RAD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed the most recent trading day at $13.94, moving -0.21% from the previous trading session.
Rite Aid (RAD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed at $13.13 in the latest trading session, marking a +1.94% move from the prior day.
Rite Aid (RAD) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed the most recent trading day at $12.42, making no change from the previous trading session.
Rite Aid (RAD) Up 12.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Rite Aid (RAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rite Aid (RAD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed the most recent trading day at $13.08, moving -1.36% from the previous trading session.
Rite Aid (RAD) Expands Coronavirus Testing Site to Virginia
by Zacks Equity Research
Rite Aid (RAD) is aggressively expanding COVID-19 testing locations, marked by the opening of its 25th site at Richmond, VA, to help curb the effects of the pandemic.
Stock Market News for Apr 20, 2020
by Zacks Equity Research
U.S. stocks surged on Friday, thanks to investor optimism over a possible cure to the deadly coronavirus and President Donald Trump's plans to gradually reopen U.S. economy.
Rite Aid's (RAD) Q4 Loss Wider Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Strong revenues at pharmacy services and retail pharmacy segments aided Rite Aid's (RAD) Q4 results. Further, management issued FY21 view, which reflects no COVID-19 impacts.